Biogen Idec to present MS data at AAN conference

Biogen Idec is to attend the American Academy of Neurology’s (AAN’s) 62nd Annual Meeting this month in order to present new data on multiple sclerosis (MS) treatments.

The company, which is responsible for MS brands such as Tysabri and Avonex, will be looking to discuss a number of commercially available drugs, as well as several promising new compounds.

In addition to highlighting the advantages of its two established MS treatments, the firm will discuss prolonged-release fampridine, a compound designed to improve walking ability among sufferers.

Results from studies into drugs such as dimethyl fumarate, PEGylated Interferon beta-1a and daclizumab will also be presented.

Dr Alfred Sandrock, senior vice-president of neurology research and development at Biogen Idec, said: “Our innovative pipeline of MS product candidates is a testament to our commitment to the MS community.”

Last month, the company commenced enrolment for a new phase IIIb study of Tysabri intended to evaluate the advantages of switching to the drug from Copaxone and Rebif.